Subscribe for email alerts

Don’t miss a single Science & Enterprise post. Sign up for our daily email alerts.

Follow us on Twitter

  • Scientists Finish the Human Genome at Last https://t.co/bTRwmNjHwP
    about 10 hours ago
  • While the public's attention for the past 18 months has been focused on Covid-19, the problem of opioid overdoses a… https://t.co/gr0q6FkShP
    about 1 day ago
  • New post on Science and Enterprise: Infographic – Drug Overdose Epidemic Accelerating https://t.co/rZP0zmFVgK #Science #Business
    about 1 day ago
  • "Unvaccinated people aren’t a random group of defectors who are trying to be deviant." @edyong209 talks to Dr. Rhea… https://t.co/FkzZWK83OE
    about 1 day ago
  • U.S. drops cases against five researchers accused of hiding ties to Chinese military https://t.co/0D4YvwvjZq
    about 2 days ago

Please share Science & Enterprise

In Case You Missed It …

(tigerlily713, Pixabay)

19 August 2018. As our infographic yesterday indicates, the opioid crisis shows few signs of abating anytime soon. And while much of the current surge in overdose deaths is from synthetic opioid drugs like fentanyl, the roots of the crisis can be traced to abuse of prescription pain drugs.

As a result, new ways of treating acute and chronic pain are badly needed. A story last week in Science & Enterprise reports on a new NIH grant to the company Peptide Logic in San Diego, developing synthetic peptides, short chains of amino acids similar to proteins. The peptides in this case act on kappa opioid receptors, pain receptors in tissue and muscles outside the central nervous system, which unlike today’s opioid pain drugs that can be addictive, do not affect the brain. The 2-year award of nearly $3 million aims to advance the technology to the point of clinical trials.

Here are other stories we covered last week:

*     *     *

Comments are closed.